Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus FULVICIN U F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus FULVICIN U F.
DIFLUCAN vs FULVICIN-U/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Category C
Category C
Antifungal
Antifungal